Auto-SCT or CAR T? A Case-Based Discussion in Relapsed DLBCL

March 24, 2025

By Krish Patel, MD
Saurabh Dahiya, MD, FACP

Opinion

Video

Panelists discuss how the choice between chimeric antigen receptor T-cell (CAR T) therapy and autologous stem cell transplantation (auto-SCT) requires careful evaluation of multiple patient-specific factors. Medical professionals consider disease type and stage, prior treatments, patient age and fitness, cytogenetic risk, donor availability, and timing. CAR T may be preferred for relapsed/refractory cases, whereas transplant remains standard for eligible newly diagnosed patients.

EP: 1.DLBCL in Focus: Transforming Outcomes With CAR T Therapy

EP: 2.Beyond Salvage: When to Move to CAR T in Relapsed DLBCL

EP: 3.Tailoring Therapy: Patient-Specific Decision-Making in Relapsed DLBCL

EP: 4.TRANSFORM and ZUMA-7: A Discussion on Efficacy and Safety of CAR T in R/R DLBCL

EP: 5.CAR T in the Real World: Clinician Perspectives on Outcomes, Toxicity, and Patient Management

EP: 6.Rethinking CAR T Timing: Insights on CAR T Efficacy and Patient Selection

EP: 7.Personalizing CAR T: Making the Right Call for Each Patient

Now Viewing

EP: 8.Auto-SCT or CAR T? A Case-Based Discussion in Relapsed DLBCL

EP: 9.Transplant-Eligible, CAR T Considered: How Do We Decide?

EP: 10.CAR T in High-Risk DLBCL: Making the Right Choice in Aggressive Disease

EP: 11.The Future of DLBCL: Innovations in Therapy and Patient Care

Video content above is prompted by the following:

How do the factors of CAR T vs transplant considerations influence your decision-making in different patient scenarios?
What factors would guide your choice between auto-SCT vs CAR T therapy?

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!